Kristan L. Lansbery, Ph.D. is an attorney with corporate and law firm leadership experience. As a Director within the legal department at Regeneron Pharmaceuticals, she oversees a team responsible for global patent protection of downstream platform technologies, trade secret protection, and freedom to operate. In that capacity, she partners with multiple research and business functions to assist the scientists, regulatory group, and other corporate stakeholders. Examples of her work at Regeneron include developing processes for multiple scientific and business groups to designate trade secrets and partnering with litigators to prepare for product launches.
Prior to Regeneron, Dr. Lansbery was a partner at Arnold & Porter LLP, where she managed teams responsible for the worldwide prosecution of life science patent portfolios. She also was lead counsel on several contentious matters before the Patent Trial and Appeal Board, and she has successfully argued ex parte appeals and litigated disputes related to polymerase chain reaction, drug-eluting stents, therapeutic antibodies, and diagnostic nucleic acids.
Dr. Lansbery’s practice is recognized by multiple publications, including IAM Patent 1000, and she has taught Biotechnology and Patent Law at Georgetown University. She earned her Ph.D. in Molecular Cell Biology from Washington University in St. Louis, and attended law school at the George Washington University.
Sub-specialties: Intellectual Property, Patents, Trade Secrets, Life Sciences, Pharmaceuticals, Antibodies, Manufacturing of biologics
[SHARE]
Expert DirectLink
-
Protecting Trade Secrets in the Medical Product Approval Process
Food and Drug Law Institute, Update Magazine [early May 2018] -
Panelist for "Antibody Patenting: Without Exception or Eligibility"
BIO IP Counsels Committee Conference, New Orleans, LA [April 11, 2018] -
Panelist for "Leveraging the Ex Parte Process"
The 2018 PTAB Bar Association Annual Conference, Washington, DC [March 22, 2018] -
Panelist for "Latest Federal Circuit Developments"
Managing IP, 3rd Annual PTAB Forum, New York, NY [May 3, 2018] -
Panelist for "Interchangeability for Biosimilars: Envisioning the Future"
American Conference Institute, 9th Annual Summit on Biosimilars, New York, NY [June 26, 2018]